FDA says OraSure's OraQuick HIV test "approvable":
This article was originally published in Clinica
Executive Summary
OraSure Technologies' OraQuick HIV-1 blood test has moved a step closer to the US market, after the FDA decided that it was "approvable". The finger stick test, which is intended to detect HIV-1 antibodies in whole blood within 20 minutes, is planned for launch in the second half of 2002, said the Bethlehem, Pennsylvania company. Final FDA product approval, however, is subject to the company submitting product labelling and resolving specific validation and design control issues.
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.